Bruker Inks Deal To Distribute Coronavirus Detection Test
Zacks Investment Research | Mar 25, 2020 10:04PM ET
Bruker Corporation (NASDAQ:BRKR) , through the Bruker-Hain Diagnostics division, inked a distribution deal with Primer Design Ltd (UK), a subsidiary of Novacyt SA, to distribute the CE-IVD-marked genesig real-time PCR coronavirus (COVID-2019) assay.
The deal has come into effect from Mar 25, 2020. Bruker-Hain Diagnostics boasts of a portfolio of DNA/RNA extraction and preparation systems and kits.
The agreement would likely make the company a key player in coronavirus diagnosis.
More about the deal
The genesig real-time PCR Coronavirus (COVID-2019) CE-IVD assay is authorized for use on Bruker-Hain Diagnostics GenoXtract (GXT) automated nucleic acid extraction devices with associated extraction kits. The shipping of the test kits to Spain, France, Germany and the U.K. has already begun.
The genesig assay has been verified for respiratory samples (nasopharyngeal swabs, oropharyngeal swabs, sputum) on commonly available laboratory thermocyclers. The kit includes all necessary reagents to deliver upto 96 results in two hours. The genesig assay has been developed for very high specificity for the 2019-nCoV virus strain that is implicated in COVID-19. The genesig test has CE-IVD clearance and is designed for in-vitro diagnostic use in Europe.
Along with its authorized GXT products for nucleic acid extraction, Bruker is now equipped to offer a solution for the diagnosis of the SARS-CoV-2 virus, the pathogen responsible for COVID-19.
Other Companies Working on Coronavirus Testing
Bio-Rad (NYSE:BIO) , through its Exact Diagnostics portfolio, recently launched a SARS CoV-2 Standard to enable laboratory assay validation of COVID-19 testing.
Quest Diagnostics (NYSE:DGX) recently announced that it is set to launch a COVID-19 test service. The test would facilitate the potential detection of nucleic acid in respiratory specimens of patients, who fulfill CDC's clinical criteria for COVID-19 testing.
LabCorp (NYSE:LH) also recently launched the 2019 Novel coronavirus (COVID-19), NAA test, for doctors and other authorized healthcare providers in the United States. The test diagnoses the presence of the underlying virus that causes COVID-19 and should benefit patients, who meet the current guidelines for the evaluation of the disease.
Price Performance
In the past year, the company’s shares have outperformed the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.